Imogam (Sanofi) Market Research Report 2026: Epidemiology, Pipeline Analysis, Trends, Strategies, & Forecasts, 2020-2025, 2025-2030F, 2035F

(MENAFN- GlobeNewsWire - Nasdaq) Key market opportunities include rising animal bite incidents due to increased human-animal interactions, growth in international travel heightening exposure to rabies-endemic regions, expanding healthcare infrastructure ensuring accessibility and distribution, and increased government investment in zoonotic disease control.

Dublin, March 10, 2026 (GLOBE NEWSWIRE) -- The "Imogam Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts" has been added to ResearchAndMarkets's offering.

The Imogam market is experiencing robust growth, with numerous factors influencing its trajectory. The historic period saw growth driven by high rabies mortality rates, limited access to vaccines, and reliance on passive immunity products. Public health vaccination programs and emergency care contributed significantly to this growth.

Imogam is a human rabies immune globulin (HRIG) product critical for post-exposure prophylaxis, providing passive immunity against rabies. Distributed through hospitals, clinics, pharmacies, and online outlets, it serves various patient demographics. The market encompasses the sale of Imogam rabies-HT 150 IU/mL vials and injections. The market value is derived from the sale of goods and services within specified geographical regions, focusing on consumption values. With its pivotal role in rabies prevention, the Imogam market is set for continued growth, meeting the needs of a diverse patient population.

Looking ahead, factors such as increasing animal bite incidents, expansion of rabies awareness campaigns, and improved access to immunoglobulins are expected to drive the market further. Government investment in zoonotic control is also a key contributor.

Animal bites have emerged as a primary driver of the Imogam market. The growing pet population and increased human-animal interactions have led to more incidents requiring medical attention. Imogam provides critical post-exposure prophylaxis for rabies in bite victims, bridging the gap until rabies vaccines take effect. Statistics from Dogster in 2024 highlighted a concerning rise in dog bite incidents, further emphasizing the role of Imogam in the market's expansion.

The increase in international travel is another significant factor propelling the Imogam market. As global mobility and tourism rise, travelers face greater exposure to rabies-endemic regions. For instance, the UK's Office for National Statistics reported a surge in overseas visitors, indicating a heightened demand for post-exposure prophylaxis, including Imogam. This trend reflects a broader need for protective measures against rabies among travelers.

The expansion of healthcare infrastructure is essential for sustaining the Imogam market. Increased healthcare funding drives better cold chain maintenance, ensuring timely and accessible rabies prophylaxis. In 2024, healthcare expenditure in the UK saw significant growth, reflecting the critical infrastructure supporting products like Imogam. Strengthened healthcare systems facilitate the efficient administration of rabies immunoglobulin and vaccines, catering to pediatric, adult, and high-risk groups.

Sanofi SA stands out as a major player in the Imogam market, with North America being the largest region in 2025. The market report covers regions such as Asia-Pacific, Western Europe, and more, outlining key countries like the USA, China, and Germany.

Reasons to Purchase

• Examine critical market characteristics, including product offerings and innovation trends.
• Analyze the supply chain, highlighting essential materials and supplier dynamics, with a competitive assessment at each level.
• Explore emerging technology trends such as automation and AI, sustainability, and digital transformation to enhance market positioning.
• Navigate the regulatory and investment landscape, examining frameworks, key bodies, policy influences, and investment trends.
• Access extensive market size data exploring both historical growth and future forecasts.
• Evaluate TAM and Market Attractiveness Scoring (MAS) to identify growth potential and strategic insights.
• Utilize detailed market segmentations and geographical breakdowns for a nuanced market understanding.
• Uncover the importance of regions like Taiwan and Southeast Asia in the global supply chain.
• Get detailed insights into competitive dynamics, market shares, and noteworthy financial transactions impacting the market.
• Benefit from company evaluations using a scoring matrix based on market share, innovation, and brand recognition.

Report Scope:

• Patient Demographics: Pediatric, Adult, High-Risk
• Application: Post-Exposure, Pre-Exposure
• Distribution Channel: Hospitals, Clinics, Online Pharmacies
• Countries: Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada
• Regions: Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
• Time Series: Includes five-year historical and ten-year forecast data

For more information about this report visit

About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

CONTACT: CONTACT: Laura Wood,Senior Press Manager... For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

MENAFN10032026004107003653ID1110841215